Busy Amgen swings another deal, this time with RNA drugging player Arrakis for 'several billion'
Less than a week after inking a $1.9 billion collaboration with Flagship’s Generate to boost its AI capabilities, Amgen is returning to the dealmaking table.
The biopharma’s newest partner is Arrakis, as the companies announced Tuesday morning they will team up to develop five RNA degrader therapeutics, with Amgen retaining an option for more. Amgen will shell out $75 million upfront and promise “several billion dollars” in biobucks if all milestones are met, though the company wouldn’t pin an exact number.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.